| |
South Africa
|
Brazil
|
Bangladesh
|
Tanzania
|
reference
|
|---|
|
All scenarios
|
|
GeneXpert coverage in new patients
|
100%
|
100%
|
0%
|
0%
|
assumption
|
|
GeneXpert coverage in previously treated
|
100%
|
100%
|
100%
|
100%
|
assumption
|
|
Guidelines
|
|
ART if HIV/TB
|
100%
|
100%
|
100%
|
100%
|
[54–61]
|
|
MDR treatment
|
100%
|
100%
|
100%
|
100%
|
[56, 59, 60, 62]
|
|
Default rate
|
1–2%
|
1–2%
|
1–2%
|
1–2%
|
[4]
|
|
Current
|
|
ART if HIV/TB
|
66%
|
54.7%
|
100%
|
73%
|
[1, 63]
|
|
MDR treatment
|
60%
|
44.5%
|
15.4%
|
12.3%
|
[1, 64]
|
|
Default rate
|
8% [6–10]
|
21% [19–23]
|
2% [1.8–2.2]
|
3% [2–4]
|
[1]
|
- ART antiretroviral treatment, HIV human immunodeficiency virus, TB tuberculosis, MDR multidrug resistant. Current coverage of ART in HIV/TB co-infection as reported in Global TB report 2014 [1], except for Brazil where this is not reported. For Brazil, we calculated the coverage of ART in HIV/TB co-infection as 84% ART coverage in general HIV patients [63] of 65% TB patients knowing their HIV status. Current coverage of MDR TB treatment was calculated from the Global TB report 2014 [1] from the prevalence of MDR among new and retreatment patients times the number of notifications for new and retreatment patients respectively. This was considered the denominator (total number of MDR patients). The numerator (patients on MDR treatment) was sourced from the Global TB report 2014. For South Africa, we added the estimated current MDR coverage levels as per the National Department of Health [64]. Note: parameters with one value are included in the model as point estimates; parameters with a value and a range were included in the model as triangular distributions; parameters with only a range of two values were included in the model as a uniform distribution
